Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and Pembrolizumab (MK-3475) Compared to Pembrolizumab Alone for Mesothelin-Positive Malignant Pleural Mesothelioma

Next Previous
Trial Profile

Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and Pembrolizumab (MK-3475) Compared to Pembrolizumab Alone for Mesothelin-Positive Malignant Pleural Mesothelioma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anetumab ravtansine (Primary) ; Pembrolizumab
  • Indications Malignant-mesothelioma
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 01 Apr 2026 Planned End Date changed from 18 Feb 2027 to 25 Feb 2027.
  • 11 Mar 2026 Planned End Date changed from 18 Sep 2026 to 18 Feb 2027.
  • 11 Mar 2026 Actual primary completion date changed from 8 Jul 2023 to 4 May 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top